Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,376 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs.
Verhoef TI, Redekop WK, van Schie RM, Bayat S, Daly AK, Geitona M, Haschke-Becher E, Hughes DA, Kamali F, Levin LÅ, Manolopoulos VG, Pirmohamed M, Siebert U, Stingl JC, Wadelius M, de Boer A, Maitland-van der Zee AH; EU-PACT group. Verhoef TI, et al. Among authors: de boer a. Pharmacogenomics. 2012 Sep;13(12):1405-17. doi: 10.2217/pgs.12.124. Pharmacogenomics. 2012. PMID: 22966889 Review.
The effectiveness of hydroxy-methylglutaryl coenzyme A reductase inhibitors (statins) in the elderly is not influenced by apolipoprotein E genotype.
Maitland-van der Zee AH, Stricker BH, Klungel OH, Kastelein JJ, Hofman A, Witteman JC, Breteler MM, Leufkens HG, van Duijn CM, de Boer A. Maitland-van der Zee AH, et al. Among authors: de boer a. Pharmacogenetics. 2002 Nov;12(8):647-53. doi: 10.1097/00008571-200211000-00009. Pharmacogenetics. 2002. PMID: 12439225
Adherence to and dosing of beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitors in the general population differs according to apolipoprotein E-genotypes.
Maitland-van der Zee AH, Stricker BH, Klungel OH, Mantel-Teeuwisse AK, Kastelein JJ, Hofman A, Leufkens HG, van Duijn CM, de Boer A. Maitland-van der Zee AH, et al. Among authors: de boer a. Pharmacogenetics. 2003 Apr;13(4):219-23. doi: 10.1097/00008571-200304000-00006. Pharmacogenetics. 2003. PMID: 12668918
Effectiveness of statins in the reduction of the risk of myocardial infarction is modified by the GNB3 C825T variant.
Peters BJ, Maitland-van der Zee AH, Stricker BH, van Wieren-de Wijer DB, de Boer A, Kroon AA, de Leeuw PW, Schiffers P, Janssen RG, van Duijn CM, Klungel OH. Peters BJ, et al. Among authors: de boer a, de leeuw pw. Pharmacogenet Genomics. 2008 Jul;18(7):631-6. doi: 10.1097/FPC.0b013e3283023fb2. Pharmacogenet Genomics. 2008. PMID: 18551043
Reasons for non-response in observational pharmacogenetic research.
van Wieren-de Wijer DB, Maitland-van der Zee AH, de Boer A, Kroon AA, de Leeuw PW, Schiffers P, Janssen RG, Psaty BM, van Duijn CM, Stricker BH, Klungel OH. van Wieren-de Wijer DB, et al. Among authors: de boer a, de leeuw pw. Pharmacoepidemiol Drug Saf. 2009 Aug;18(8):665-71. doi: 10.1002/pds.1764. Pharmacoepidemiol Drug Saf. 2009. PMID: 19462400
Genetic determinants of response to statins.
Peters BJ, Klungel OH, de Boer A, Maitland-van der Zee AH. Peters BJ, et al. Among authors: de boer a. Expert Rev Cardiovasc Ther. 2009 Aug;7(8):977-83. doi: 10.1586/erc.09.83. Expert Rev Cardiovasc Ther. 2009. PMID: 19673675 Review.
1,376 results